These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 11574441

  • 1. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
    Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N, SNK-860 Diabetic Neuropathy Study Group.
    Diabetes Care; 2001 Oct; 24(10):1776-82. PubMed ID: 11574441
    [Abstract] [Full Text] [Related]

  • 2. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
    Kato N, Mizuno K, Makino M, Suzuki T, Yagihashi S.
    Diabetes Res Clin Pract; 2000 Oct; 50(2):77-85. PubMed ID: 10960717
    [Abstract] [Full Text] [Related]

  • 3. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K, Kato N, Makino M, Suzuki T, Shindo M.
    J Diabetes Complications; 1999 Oct; 13(3):141-50. PubMed ID: 10509874
    [Abstract] [Full Text] [Related]

  • 4. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.
    Jaspan JB, Herold K, Bartkus C.
    Am J Med; 1985 Nov 15; 79(5A):24-37. PubMed ID: 3000176
    [Abstract] [Full Text] [Related]

  • 5. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
    Sekiguchi K, Kohara N, Baba M, Komori T, Naito Y, Imai T, Satoh J, Yamaguchi Y, Hamatani T, Ranirestat Group.
    J Diabetes Investig; 2019 Mar 15; 10(2):466-474. PubMed ID: 29975462
    [Abstract] [Full Text] [Related]

  • 6. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.
    Jaspan JB, Towle VL, Maselli R, Herold K.
    Metabolism; 1986 Apr 15; 35(4 Suppl 1):83-92. PubMed ID: 3083212
    [Abstract] [Full Text] [Related]

  • 7. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV, Snksen PH, Boulton AJ, Macleod A, Beg M, Bochenek W, Graepel GJ, Gonen B.
    J Diabetes Complications; 1993 Apr 15; 7(3):170-8. PubMed ID: 8343611
    [Abstract] [Full Text] [Related]

  • 8. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
    Bril V, Buchanan RA.
    Diabetes Care; 2006 Jan 15; 29(1):68-72. PubMed ID: 16373898
    [Abstract] [Full Text] [Related]

  • 9. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
    Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, Shigeta Y.
    Diabetes Care; 2006 Jul 15; 29(7):1538-44. PubMed ID: 16801576
    [Abstract] [Full Text] [Related]

  • 10. Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat.
    Kuzumoto Y, Kusunoki S, Kato N, Kihara M, Low PA.
    Diabetologia; 2006 Dec 15; 49(12):3085-93. PubMed ID: 17063327
    [Abstract] [Full Text] [Related]

  • 11. The effect of an aldose reductase inhibitor (Sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study.
    Christensen JE, Varnek L, Gregersen G.
    Acta Neurol Scand; 1985 Feb 15; 71(2):164-7. PubMed ID: 3920861
    [Abstract] [Full Text] [Related]

  • 12. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial.
    Fagius J, Brattberg A, Jameson S, Berne C.
    Diabetologia; 1985 Jun 15; 28(6):323-9. PubMed ID: 3930330
    [Abstract] [Full Text] [Related]

  • 13. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.
    Lewin IG, O'Brien IA, Morgan MH, Corrall RJ.
    Diabetologia; 1984 Jun 15; 26(6):445-8. PubMed ID: 6432615
    [Abstract] [Full Text] [Related]

  • 14. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function.
    Jaspan J, Maselli R, Herold K, Bartkus C.
    Lancet; 1983 Oct 01; 2(8353):758-62. PubMed ID: 6137601
    [Abstract] [Full Text] [Related]

  • 15. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
    Sima AA, Prashar A, Nathaniel V, Bril V, Werb MR, Greene DA.
    Diabet Med; 1993 Mar 01; 10(2):115-21. PubMed ID: 8458187
    [Abstract] [Full Text] [Related]

  • 16. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients.
    Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, Pfeifer MA, Vukadinovic C, Bernstein L, Schneider M, Liang KY, Gabbay KH, Rubenstein AH, Porte D.
    N Engl J Med; 1983 Jan 20; 308(3):119-25. PubMed ID: 6401351
    [Abstract] [Full Text] [Related]

  • 17. Improvement in peripheral nerve function after one year of Sorbinil.
    Gieron MA, Malone JI, Lowitt S, Korthals JK.
    Neuroreport; 1991 Jun 20; 2(6):348-50. PubMed ID: 1655107
    [Abstract] [Full Text] [Related]

  • 18. Fidarestat. Sanwa Kagaku/NC Curex/Sankyo.
    Giannoukakis N.
    Curr Opin Investig Drugs; 2003 Oct 20; 4(10):1233-9. PubMed ID: 14649216
    [Abstract] [Full Text] [Related]

  • 19. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
    Sundkvist G, Armstrong FM, Bradbury JE, Chaplin C, Ellis SH, Owens DR, Rosén I, Sönksen P.
    J Diabetes Complications; 1992 Oct 20; 6(2):123-30. PubMed ID: 1611136
    [Abstract] [Full Text] [Related]

  • 20. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report.
    Valensi P, Le Devehat C, Richard JL, Farez C, Khodabandehlou T, Rosenbloom RA, LeFante C.
    J Diabetes Complications; 2005 Oct 20; 19(5):247-53. PubMed ID: 16112498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.